Ascentage Pharma sets board meeting on 2025 results

Ascentage Pharma Group International has called a board meeting for March 25, 2026.

Accepted by SEC EDGAR 03/16/2026 - 06:30 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ascentage Pharma Group International has called a board meeting for March 25, 2026. At this meeting, the board plans to review and, if appropriate, approve the Group’s annual results for the year ended December 31, 2025 and consider declaring a final dividend. The notice also confirms the current composition of the board, including Chairman and Executive Director Dr. Yang Dajun and a mix of non-executive and independent non-executive directors.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ascentage Pharma (AAPG) announce in its March 2026 Form 6-K?

Ascentage Pharma announced that its board will meet on March 25, 2026 to consider approving the Group’s annual results for the year ended December 31, 2025 and to consider the declaration of a final dividend, if any, for shareholders.

When is Ascentage Pharma’s board meeting to review 2025 annual results?

The board meeting is scheduled for Wednesday, March 25, 2026. At this meeting, directors will review the Group’s annual results for the year ended December 31, 2025 and discuss whether to approve them and consider any potential final dividend.

Will Ascentage Pharma (AAPG) consider a final dividend at the March 25, 2026 meeting?

Yes. The board will consider the declaration of a final dividend, if any, at the March 25, 2026 meeting. This discussion will occur alongside review and potential approval of the Group’s annual results for the 2025 financial year.

Which financial period’s results is Ascentage Pharma’s board reviewing?

The board will review the Group’s annual results for the year ended December 31, 2025. These results will be considered for approval at the March 25, 2026 board meeting, along with a discussion about whether to declare a final dividend.

Who leads the board of Ascentage Pharma Group International?

The board is led by Dr. Yang Dajun, who serves as Chairman and Executive Director. The board also includes non-executive directors and independent non-executive directors, providing governance oversight for the Group’s operations and financial reporting decisions.

Where is Ascentage Pharma Group International incorporated and listed?

Ascentage Pharma Group International is incorporated in the Cayman Islands with limited liability and is listed in Hong Kong under stock code 6855. The announcement was released through Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of March 2026

Commission File Number: 002-023311

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

On March 13, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued an announcement entitled, “Notice of Board Meeting”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Announcement dated March 13, 2026

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: March 13, 2026	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

Exhibit 99.1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

NOTICE OF BOARD MEETING

The board of directors (the “Board”) of Ascentage Pharma Group International (the “Company”, together with its subsidiaries, collectively the “Group”) hereby announces that a meeting of the Board will be held on Wednesday, March 25, 2026, for the purpose of, among other things, considering and, if appropriate, approving the annual results of the Group for the year ended December 31, 2025 and considering the declaration of a final dividend, if any.

By order of the Board

Ascentage Pharma Group International

Dr. Yang Dajun

Chairman and Executive Director

Suzhou, People’s Republic of China, March 13, 2026

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon DazhongNote1 as non-executive Directors, and Mr. Ye Changqing, Mr. Ren Wei, Dr. David SidranskyNote2, Ms. Marina S. Bozilenko, Dr. Debra Yu and Dr. Marc E. Lippman, MD as independent non-executive Directors.

Notes: 1. Dr. Lu Simon Dazhong satisfy the independence requirements of the U.S. Securities and Exchange Commission and Nasdaq corporate governance requirements

2. Dr. David Sidransky is the Lead Independent Non-Executive Director of the Company.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 ANNOUNCEMENT DATED MARCH 13, 2026 6.0 KB